SOPHARMA AD hereby informs that from 29 July 2015 up to and including 05 August 2015 the Company bought 350 own shares representing 0.00026% of the share capital of the Company, at a total value of 975.90 BGN on the Bulgarian Stock Exchange, the average price per share was 2.703 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 175 182, representing 3.84% of the share capital of the Company.

SOPHARMA AD hereby informs that from 20 August 2015 up to and including 26 August 2015 the Company bought 500 own shares representing 0.0004% of the share capital of the Company, at a total value of 1320.00 BGN on the Bulgarian Stock Exchange, the average price per share was 2.64 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 175 682, representing 3.84% of the share capital of the Company.

Sopharma AD notifies that for August 2015 the Company recorded an increase of sales revenues of 1% compared to the same month of 2014, including 5% decrease of domestic sales and 4% increase of export sales.

For the first eight months of this year, revenues from sales decreased by 15% compared to the same period of 2014, including 9% increase of domestic sales and a 26% decrease of export sales.

SOPHARMA AD hereby informs that from 3 September 2015 up to and including 9 September 2015 the Company bought 43 614 own shares representing 0.032% of the share capital of the Company.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 219 296, representing 3.87% of the share capital of the Company.

The Board of Directors of Sopharma notifies that on its meeting carried out on September 18, 2015 it took a decision to initiate a procedure for merging Momina krepost AD, VAT number 104055543 based in the city of Veliko Tarnovo on 23, “Magistralna” Blvd. into Sopharma AD, under the regulation of the Commercial Code and art. 122 and the following of the Law on Public Offering of Securities and chooses “Elana Trading” AD VAT number 831470130, based on 4, Kuzman Shapkarev Str. for a consultant in relation to the merger.

The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that in order to facilitate the operational work of Sopharma AD, the Board of Directors decided to appoint Ivan Badinski, MPharm, director of Cooperation and Licenses, Sopharma AD as procurator of the company. Mr. Badinski has been working in Sopharma AD since 1997 as a member of the Board of Directors of the Company.

SOPHARMA AD hereby informs that from 11 December 2014 up to and including 17 December 2014 the Company bought 510 own shares representing 0.00039% of the share capital of the Company, to the total value of 1964.01 BGN on the Bulgarian Stock Exchange, the average price per share was 3.85 BGN. The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010. The total number of treasury shares after these transactions is 5 113 553, representing 3.87% of the share capital of the Company.

Sopharma AD notifies that for September 2015 the Company recorded a decrease of sales revenues of 35% compared to the same month of 2014, including 1% increase of domestic sales and 48% decrease of export sales.

For the first nine months of this year, revenues from sales decreased by 18% compared to the same period of 2014, including 2% increase of domestic sales and a 27% decrease of export sales.

Sopharma AD notifies that for December 2015 the Company recorded an increase of sales revenues of 8% compared to the same month of 2014, including 16% increase in domestic sales and 32% increase in export sales. The increase in export sales is mainly due to an increase in sales on the Russian market by 45%. The management has planned to sustain the export activity in the months January and December 2016, as well as to improve the rhythm of sales in Russia in the summer months.

Sopharma AD notifies that at the start of the financial year Sopharma’s Commercial Director has left the management of the Company. Vladimir Stoychev joined the team of Sopharma AD in September 2001 as a warehouse manager for export goods. Later he was transferred to the position of Head of the Kazakhstan office. His good work lead eventually to his promotion to Commercial Director of Sopharma AD in 2007. The management team of the company wishes Mr. Stoychev success in his new professional endeavors.